We are live on ! Find out more
ALXO icon

ALX Oncology
ALXO

76 hedge funds and large institutions have $160M invested in ALX Oncology in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,557% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $61K

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

1% more funds holding

Funds holding: 75 → 76 (+1)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.03% less ownership

Funds ownership: 83.91% → 80.88% (-3%)

38% less capital invested

Capital invested by funds: $258M → $160M (-$97.8M)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
23
Reduced
22
Closed
10
Calls
$1.01M
Puts
$61K
Net Calls
+$950K
Net Calls Change
+$297K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$1.21M
2
Morgan Stanley
Morgan Stanley
New York
+$492K
3
BlackRock
BlackRock
New York
+$294K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$246K
5
HSBC Holdings
HSBC Holdings
United Kingdom
+$192K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$3.75M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.92M
3
Deutsche Bank
Deutsche Bank
Germany
-$991K
4
Millennium Management
Millennium Management
New York
-$672K
5
Goldman Sachs
Goldman Sachs
New York
-$264K
Name Holding Trade Value Shares
Change 		Change in
Stake
VP
1
venBio Partners
California
$46.6M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$26.8M -$2.92M -538,592 -9%
VC
3
Vivo Capital
California
$20.3M – – –
O
4
OrbiMed
New York
$13.8M – – –
BlackRock
5
BlackRock
New York
$8.85M +$294K +54,259 +3%
RG
6
Redmile Group
California
$6.16M – – –
B
7
Braidwell
Connecticut
$6M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.84M +$8.94K +1,648 +0.2%
LGM
9
Logos Global Management
California
$4.8M – – –
CAM
10
Cormorant Asset Management
Massachusetts
$2.94M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.13M -$6.68K -1,231 -0.3%
Citadel Advisors
12
Citadel Advisors
Florida
$2.04M +$1.21M +222,934 +110%
State Street
13
State Street
Massachusetts
$1.87M +$43.1K +7,940 +2%
Morgan Stanley
14
Morgan Stanley
New York
$1.6M +$492K +90,637 +37%
Federated Hermes
15
Federated Hermes
Pennsylvania
$1.21M -$19.6K -3,610 -1%
Renaissance Technologies
16
Renaissance Technologies
New York
$1.02M +$161K +29,700 +16%
Northern Trust
17
Northern Trust
Illinois
$919K -$6.39K -1,178 -0.6%
Los Angeles Capital Management
18
Los Angeles Capital Management
California
$704K – – –
Charles Schwab
19
Charles Schwab
California
$676K -$135K -24,817 -15%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$647K +$246K +45,367 +51%
Goldman Sachs
21
Goldman Sachs
New York
$629K -$264K -48,640 -27%
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
$453K -$22.8K -4,200 -4%
N
23
Nuveen
North Carolina
$421K -$56.5K -10,411 -11%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$346K -$217 -40 -0.1%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$250K +$123K +22,675 +77%
1
2 3 4

ALXO Hedge Fund Activity: Q3 2023 in Review

76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2023, worth a combined $160M — down 38% from $258M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ALXO positions and 10 closed out — a net gain of 2 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $1.21M. The largest seller was Artal Group, exiting entirely with an estimated $3.75M sold.

  • 76 institutional investors held ALX Oncology (ALXO) as of Q3 2023, up from 75 in Q2 2023.
  • Funds reported $160M of ALX Oncology stock for Q3 2023, down 38% quarter-over-quarter.
  • 12 funds opened new ALX Oncology positions in Q3 2023 and 10 closed out, a net change of +2 holders.
  • The largest ALX Oncology buyer in Q3 2023 was Citadel Advisors, an estimated $1.21M added.
  • The largest ALX Oncology seller in Q3 2023 was Artal Group, an estimated $3.75M sold.

Based on aggregated 13F filings for Q3 2023.